Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory committee cancellations

Executive Summary

A Psychopharmacologic Drugs Advisory Committee review of Wyeth's pending antidepressant desvenlafaxine scheduled for Sept. 8 has been canceled, Wyeth announces Aug. 22. FDA deemed the meeting unnecessary because "questions that they had were answered with further review of the data," firm says. Company still expects to launch the Effexor follow-on in 2007. The agency also recently cancelled a Sept. 7 psychopharm committee review of J&J's antipsychotic paliperidone (1"The Pink Sheet" July 24, 2006, p. 6). Additionally, Schering-Plough announced Aug. 21 that a planned Sept. 11 Anti-Infective Drugs Advisory Committee review of garenoxacin (proposed trade name Geninax) has been cancelled after the company withdrew the NDA. Schering says it may meet with FDA in the future about a resubmission of the antibiotic...

You may also be interested in...



J&J Aims For Virology Leadership, But Pipeline Covers Traditional Strengths

Johnson & Johnson is positioning itself to become a major player in the virology market through its recently approved protease inhibitor Prezista and the development of two non-nucleoside reverse transcriptase inhibitors

Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions

Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.

Cara Placing Korsuva Hopes On Oral Formulation, Broad Pruritis Label

I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel